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pathologies. Of 30 AF positive lesions we were able to deﬁne the sub-
group of 19 locations with speciﬁc spectroscopy pattern corresponding 
wit non-malignant histology. NBI bronchoscopy is not simple to inter-
pret but gives promising results in discrimination between malignant 
and benign endobronchial tissue. 
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Background: EBUS-TBNA was reported to have higher diagnostic ac-
curacy in lymph node (LN) staging of lung cancer compared to CT and 
PET. We conducted a prospective study to compare EBUS-TBNA with 
PET/CT in mediastinal LN staging, especially focused on histologic 
types of NSCLC. 
Methods: EBUS-TBNA was performed in 73 potentially operable 
NSCLC patients (pts) (M/F 60/13, median age 64 yrs). Chest CT and 
PET/CT were done before EBUS-TBNA. In case mediastinal LN me-
tastasis was not proved by EBUS-TBNA, surgery was performed. 
Results: Out of 73 pts, 34 had adenocarcinoma (ADC) and 32 had 
squamous cell ca (SCC)(large cell ca n=4, non-small cell ca unspeci-
ﬁed, n=3). One hundred twenty-six mediastinal LNs (2R = 6, 2L=1, 
4R=44, 4L=26, 7N=49) were sampled by EBUS-TBNA in 73 pts. 
EBUS-TBNA demonstrated metastasis in 34 LN stations in 23pts 
and missed 1 N2(+) patient (station 7, SCC). Overall, EBUS-TBNA 
showed higher diagnostic accuracy than PET/CT in mediastinal LN 
staging (Table, p=0.0075). EBUS-TBNA demonstrated LN metastasis 
in 3 PET (-) patients. All 3 pts had ADC. In ADC, positive predictive 
value (PPV) and negative predictive value (NPV) of PET/CT were 
81.3% and 83.3% respectively. In SCC, PPV of PET/CT was very low 
(33.3%) and NPV was high (94.1%). 
Conclusion: EBUS-TBNA is useful in mediastinal LN staging espe-
cially for the pts with mediastinal PET (-) adenocarcinoma and PET (+) 
NSCLC.
  Sensitivity Speciﬁcity PPV NPV Accuracy
Total, n=73 PET/CT 83.3(20/24) 69.3(34/49) 57.1(20/35) 89.5(34/38) 74.0(54/73)
 EBUS-TBNA 95.8(23/24) 100(49/49) 100(23/23) 98.0(49/50) 98.6(72/73)
ADC, n=34 PET/CT 81.3(13/16) 83.3(15/18) 81.3(13/16) 83.3(15/18) 82.4(28/34)
 EBUS-TBNA 100(16/16) 100(18/18) 100(16/16) 100(18/18) 100(34/34)
SCC, n=32 PET/CT 83.3(5/6) 61.5(16/26) 33.3(5/15) 94.1(16/17) 65.6(21/32)
 EBUS-TBNA 83.3(5/6) 100(26/26) 100(5/5) 96.3(26/27) 96.9(31/32)
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Backgroud: We had previously developed the possibility of use of a 
photodynamic diagnosis (PDD) system using a tumor-selective photo-
sensitizer and laser irradiation for the early detection and photodynamic 
therapy (PDT) of centrally located early lung cancers. Recently, we 
established the autoﬂuorescence diagnosis system integrated into a 
videoendoscope (SAFE-3000) as a very useful technique for the early 
diagnosis of lung cancer. 
Patients and Methods: Thirty-four patients (45 lesions) with cen-
trally located early lung cancer (Squamous cell carcinoma, carcinoma 
in situ, TisN0M0, stage 0) received PDT using the second-generation 
photosensitizer, talaporﬁn sodium (NPe6), and a diode laser (664 nm). 
Just before the PDT, we deﬁned the tumor margin accurately using the 
novel PDD system SAFE-3000 with NPe6 and a diode laser (408 nm).
Results: Red ﬂuorescence emitted from the tumor by excitation of the 
photosensitizer by the diode laser (408 nm) from SAFE-3000 allowed 
accurate determination of the tumor margin just before the PDT. The 
complete remission (CR) rate following NPe6-PDT in the cases with 
early lung cancer was 93.3% (42 /45 lesions). We also conﬁrmed the 
loss of red ﬂuoresce from the tumors immediately after the PDT using 
SAFE-3000. We conﬁrmed that all the NPe6 in the tumor had been 
excited and photobleached by the laser irradiation (664 nm) and that no 
additional laser irradiation was needed for curative treatment. 
Conclusions: This novel PDD system using SAFE-3000 and NPe6 
improved the quality and efﬁcacy of PDT and avoided misjudgment of 
the dose of the photosensitizer or laser irradiation in PDT. 
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Background: Radiofrequency ablation therapy (RFA) is widely ap-
plied for the treatment thoracic malignancies as a modality of local 
control therapy lately. RFA procedure itself is thought to be almost safe. 
However, assessment of therapeutic efﬁcacy following RFA procedure 
is not well established. 
Lately, the use of FDG-PET-CT scan has been advocated for early 
tumor diagnosis or early recurrent cancer detection in the ﬁeld of 
thoracic malignancies. Although several studies showing the beneﬁt 
of FDG-PET-CT scan in RFA for thoracic malignancies have been 
reported, optimal timing of examinations after RFA, appropriate fol-
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low-up schedule are still unknown. We are currently conducting Phase 
I/II study for RFA for thoracic malignancy using FDG-PET-CT as an 
evaluation procedure. Here we report the result of our study and useful-
ness of FDG-PET-CT scan as an evaluation procedure after RFA.
Method: In the last two years, we performed RFA on 11 patients who 
had thoracic malignancy. We evaluated 9 patients out of 11 who had 
positive FDG accumulation to tumors in this study. They were 8 males 
and 1 female with a mean age of 75.2 years (range of 65-81years old). 
Two patients had primary lung cancer, 4 patients had recurrent lung 
cancer, 3 patients had metastatic tumor. Tumor size were 0.8-2.5cm in 
diameters (mean: 1.64cm). All patients were not candidate to surgery 
because of their cardiac or pulmonary dysfunctions and underwent CT-
guided percutaneous RFA under local anesthesia.
Result: No mortality and no major morbidity were noted. Morbidity 
was observed 5 cases out of 9 patients (55.6%) included 3 patients with 
pneumothorax without drainage, 1 patient who had chest pain dur-
ing ablation and 1 patient who had fever without any treatment after 
RFA. Obvious decrease of FDG accumulation was observed in early 
examination (7-14days) after RFA in 8 patients out of 9, only 1 patient 
showed stable accumulation of FDG.
After ‚S-16months (mean follow up period were 9.75M) follow up 
periods, those 8 patients had no clear local recurrence. 
Conclusion: RFA for thoracic malignancy seems to be safe and fea-
sible. Early examinations of FDG-PET-CT scan after RFA may be use-
ful for evaluation of a local control. To clarify the effectiveness of RFA 
on patients’ survival, it still is needed that larger series clinical trial and 
much longer observation. 
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Background: An EAP was developed for the use of pemetrexed (P) in 
patients with MPM before and during review by regulatory agencies. 
Previous studies showed promising results for the use of single-agent 
P or the combination of P+platinum for chemonaive pts with MPM. 
The phase II study (Scagliotti 2003) of P showed a response rate (RR) 
of 14.1% (95% CI 6.6, 25.0), time to progressive disease (TtPD) of 4.7 
mos (95% CI 4.2, 5.8), and median survival time of 10.7 mos (95% 
CI 7.7, 14.5), with a 1-yr survival rate of 47.8%. The phase III study 
of P+cisplatin (Cis) versus Cis in MPM demonstrated a signiﬁcantly 
different RR (41.3% vs 16.7% p<0.001), TtPD (5.7 mos vs 3.9 mos, 
p=0.001), and survival beneﬁt (median survival: 12.1 mos vs 9.3 mos, 
p=0.020; 1-yr survival: 50.3% vs 38.0%, p=0.012) in favor of P+Cis 
(Vogelzang 2003). The EAP provided access to P alone or P plus Cis or 
carboplatin (Cb) for 3312 pts in 13 countries. Safety and efﬁcacy data 
for chemonaïve pts receiving P or P+platinum are summarized in this 
abstract.
Methods: Eligible pts had histologic or cytologic diagnosis of MPM 
not amenable to curative surgery. P 500 mg/m2 alone or in combination 
with either Cis 75 mg/m2 or Cb AUC 5 was given on day 1 of each 21-
day cycle, with standard premedication consisting of vitamin B12, folic 
acid, and dexamethasone. Investigator-determined best response (RR) 
and survival data (with censoring) were recorded at the end of study 
participation. Myelosuppression data (NCI CTC, version 2.0) were also 
collected.
Results: In this nonrandomized, open-label study 2023 chemonaïve 
pts received ≥ 1 dose of P (319 pts), P+Cis (843 pts) or P+Cb (861 
pts) and were evaluable for safety. Of the study participants, 247 P pts, 
745 P+Cis pts, and 752 P+Cb pts were evaluable for efﬁcacy. Baseline 
characteristics, and efﬁcacy and safety data are summarized in the 
table.
Conclusions: In this large, nonrandomized study, all three treatment 
arms (P, P+Cis, and P+Cb) had clinically similar one-year survival 
rates, whereas the combination arms had higher response rates than 
P alone. These results conﬁrm the efﬁcacy of P or P+platinum in the 
treatment of chemonaive pts with MPM. 
 P P+Cis P+Cb
Median age (years) (range) 69 (39-87) 62 (24-78) 66 (35-89)
Male (%) 78.1 85.3 80.5
Karnofsky performance status ≥ 80, 
% of pts* 71.6 86.8 85.8
RR, % of pts (95% CI) 10.5 (7. 0, 15.0) 26.3 (23.2, 29.6) 21.7 (18.8, 24.8)
Disease control rate (responders 
+SD), % of pts (95% CI) 59.1 (52.7, 65.3) 77.7 (74.6, 80.7) 75.8 (72.6, 78.8)
One-year survival rate, % (95% CI) 58.6 (43.4, 73.8) 63.1 (50.7, 75.5) 64.0 (53.3, 74.6)
Median TtPD (months) (95% CI) 6.0 (4.6, 7.2) 7.0 ( 6.7, 8.3) 6.9 (6.6, 7.7)
Leukopenia, Gr 3/4, % of pts 14.7 13.1 21.0
Neutropenia, Gr 3/4, % of pts 17.3 23.9 36.1
Thrombocytopenia, Gr 3/4, % of pts 2.9 5.0 14.3
Anemia, Gr 3/4, % of pts 7.5 7.2 14.3
* >90% of pts in each treatment arm were assessed for performance status.
